Does Anthem Cover Zepbound? CarelonRx, Step Therapy, and the Appeal That Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Anthem (Elevance Health) covers Zepbound on Tier 3 with PA processed through CarelonRx, its in-house PBM
• Step therapy through Wegovy or Saxenda is standard on most Anthem plans
• Step-therapy exceptions are available under federal law within 72 hours when documented
• Anthem-administered self-funded employer plans frequently carve out AOM benefits
• The OSA pathway (December 2024 FDA approval) is the strongest route for previously-denied patients

Direct answer

Anthem covers Zepbound on its standard commercial formulary at Tier 3 with prior authorization through CarelonRx, the Elevance Health pharmacy benefit manager. As of May 2026, confirm with your specific plan. The defining feature of Anthem's process is aggressive step therapy: most plans require a 3-month trial of Wegovy or Saxenda before approving Zepbound. Self-funded employer plans administered by Anthem frequently include AOM exclusions that no clinical appeal can overcome. The realistic paths forward are: complete step therapy, request a step-therapy exception with documented prior treatment failure, pursue the OSA indication if eligible, or move to Lilly Direct self-pay or compounded tirzepatide.

Table of contents

1. Anthem, Elevance, and CarelonRx: how they fit together
2. The 14-state Anthem footprint
3. Step-therapy mechanics on Anthem plans
4. Step-therapy exceptions that work
5. Prior authorization criteria in detail
6. Why employer carve-outs override clinical appeals
7. The OSA pathway through Anthem
8. Cost scenarios across Anthem plan types
9. Anthem Medicare Advantage
10. FAQ
11. Sources

Anthem, Elevance, and CarelonRx: how they fit together

Anthem Inc. rebranded to Elevance Health in June 2022 to reflect its diversified health-services business. The branded "Anthem" plans (Anthem Blue Cross, Anthem Blue Cross and Blue Shield) operate as Blue Cross Blue Shield licensees in 14 states. The corporate parent is Elevance Health.

CarelonRx is Elevance's pharmacy benefit manager, previously known as IngenioRx. The IngenioRx-to-CarelonRx transition was completed in 2023. When you submit a Zepbound prior authorization on an Anthem plan, the actual decision happens at CarelonRx.

This affects two practical things:

• Appeal letters should reference CarelonRx Clinical Review
• Provider portals route Anthem PAs to the CarelonRx queue

The 14-state Anthem footprint

Anthem-branded Blue plans operate as BCBS licensees in 14 states:

California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York (parts), Ohio, Virginia, Wisconsin.

Outside these states, Elevance operates other plans (Wellpoint, Empire BCBS, federal contracts) but the "Anthem" brand is regional. If your card says Anthem, you're in one of the 14 states. If it says BCBS but you don't see Anthem, you're under a different BCBS licensee with different rules.

Step-therapy mechanics on Anthem plans

Anthem's standard step-therapy sequence for Zepbound (2026 edition):

Step	Required drug	Trial duration	Advancement criteria
1	Phentermine (some plans) or Saxenda	3 months	Inadequate response or intolerance
2	Wegovy	3 months at maintenance dose	Inadequate response or intolerance
3	Zepbound approved	-	-

The 3-month Wegovy trial is the most contentious. Patients starting from scratch face a real 3-month delay before Zepbound consideration unless they qualify for a step-therapy exception.

Some Anthem plans (typically larger fully-insured commercial plans) have begun reducing step-therapy requirements after the SURMOUNT-OSA approval expanded the clinical case for tirzepatide. Plan-specific check before assuming.

Step-therapy exceptions that work

Federal regulations require Anthem to offer step-therapy exceptions and respond within 72 hours (24 hours for urgent cases). Approval requires documenting one of the following:

• The required step drug is contraindicated for this patient
• The patient has previously tried and discontinued the step drug due to inadequate response or adverse effects
• The required step drug is expected to be ineffective based on patient-specific characteristics
• The required step drug is expected to cause harm

The most successful exception arguments cite prior GLP-1 trials elsewhere. A patient who tried Ozempic or Wegovy on a previous plan has standing to skip the Wegovy step. Anthem does not require the prior trial was paid by Anthem.

Submit the exception with the initial PA, not after a denial. This collapses two cycles into one.

Prior authorization criteria in detail

Anthem's published PA criteria via CarelonRx (current May 2026):

• BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (T2D, hypertension, dyslipidemia, OSA, cardiovascular disease)
• Age ≥ 18
• Documented prior comprehensive weight-management intervention (6 months of diet, exercise, behavioral)
• Step-therapy completed or exception granted
• Prescriber attestation of continued lifestyle counseling
• No concurrent GLP-1 use
• Reauthorization at 6 months: ≥ 5% baseline weight loss

Why employer carve-outs override clinical appeals

Anthem administers self-funded employer plans as a TPA. Self-funded employers choose whether to cover AOMs. Approximately 40-50% of Anthem-administered self-funded plans exclude AOMs as of 2026 estimates.

If your plan booklet (Summary Plan Description) lists "weight loss medications" under exclusions, no PA, appeal, or step-therapy exception will produce coverage under the weight-loss indication. Coverage is a benefits-level decision, not a clinical one.

The paths forward when this happens:

• Pursue the OSA indication if you have documented sleep apnea
• Talk to HR about adding AOM benefits at the next renewal cycle
• Move to Lilly Direct ($499/mo) or compounded tirzepatide ($199-$399/mo)

The OSA pathway through Anthem

The December 2024 FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea created a coverage path that bypasses some Anthem plan AOM exclusions. The OSA indication treats the prescription as sleep apnea treatment rather than weight loss.

Anthem began updating OSA criteria during Q1-Q2 2025. Requirements typically include:

• Polysomnography or home sleep apnea test showing AHI ≥ 15 events/hour
• BMI ≥ 30
• ICD-10 G47.33 on the prescription and PA submission
• Trial of CPAP or documented contraindication (varies by plan)

Cite the SURMOUNT-OSA trial (Malhotra et al. 2024, NEJM) in the prior authorization: tirzepatide reduced AHI by approximately 25 events/hour vs 5 events/hour with placebo.

Cost scenarios across Anthem plan types

Scenario	Monthly cost
Anthem Tier 3 fixed copay, PA cleared	$60-$100
Anthem PPO, after deductible met	$50-$80
Anthem HDHP before deductible	~$1,086 retail until deductible
Anthem Tier 3 with Lilly savings card	$25
Anthem Medicare Advantage, OSA indication	$47-$100 Tier 3 copay
Anthem AOM-excluded plan, no OSA	Cash pay only
Lilly Direct vials	$499
Compounded tirzepatide (503A)	$199-$399

Anthem Medicare Advantage

Anthem Medicare Advantage prescription drug plans follow CMS Part D rules. The Medicare weight-loss exclusion applies; Anthem MA plans cannot cover Zepbound for weight loss alone.

For Anthem MA members with OSA, the December 2024 FDA approval opened coverage. Most Anthem MA plans added Zepbound to formulary for OSA in 2025-2026 plan years. Requirements match the commercial OSA pathway with the additional Medicare-specific elements: standard Part D appeal process if denied, redetermination request through Anthem MA, then external review by CMS-contracted independent review entity.

Contrary view: Anthem's step therapy isn't always wrong

Step therapy gets attacked broadly. The Anthem version has defensible elements.

Wegovy is a different molecule (semaglutide) with a different side-effect profile than tirzepatide. A patient who has not tried semaglutide doesn't know which they tolerate better. Some patients have less GI distress on semaglutide; others on tirzepatide. The Wegovy step generates useful comparison data when there's no prior history.

Cost-wise, Wegovy is often available at a lower self-pay rate than Zepbound. A patient who responds well to Wegovy may not need Zepbound at all.

The legitimate complaint isn't the existence of step therapy but its inflexibility. Patients with prior GLP-1 trial documentation should clear the exception quickly. When that doesn't happen, the system is failing on execution, not philosophy.

Decision framework

If you're submitting a first-time Anthem PA: If you have any prior GLP-1 history, include a step-therapy exception request with the initial PA.

Denied for step therapy: File the exception with documented prior treatment failure or contraindication. Federal law requires 72-hour response.

Denied for AOM exclusion: Look at the OSA indication. If not eligible, move to Lilly Direct or compounded.

If you have Anthem Medicare: The weight-loss exclusion blocks; the OSA path may open coverage if you qualify.

FAQ

Does Anthem cover Zepbound? Yes on standard commercial formulary at Tier 3 with PA. Coverage depends on employer plan AOM benefits and PA approval.

Who decides the PA? CarelonRx, Elevance Health's in-house PBM.

What is the step therapy? Most Anthem plans require Wegovy or Saxenda trial first. Some require phentermine.

Can I skip step therapy? Yes, with a step-therapy exception. Federal law requires 72-hour response.

What does Zepbound cost with Anthem? $60-$100 Tier 3 copay typically; $25 with Lilly savings card.

Does Anthem cover Zepbound for OSA? Yes on most plans after the December 2024 FDA approval. Requires sleep-study documentation.

Does Anthem cover compounded tirzepatide? No.

Which states have Anthem plans? 14 states: CA, CO, CT, GA, IN, KY, ME, MO, NV, NH, NY (parts), OH, VA, WI.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for Treatment of Obesity. NEJM. 2022.
2. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea and Obesity. NEJM. 2024.
3. Wilding JPH et al. Semaglutide for Treatment of Obesity. NEJM. 2021.
4. Anthem (Elevance Health) Commercial Drug List. 2026 edition.
5. CarelonRx Pharmacy Clinical Policies. 2026.
6. Elevance Health corporate disclosures. Rebranding from Anthem Inc. June 2022.
7. FDA. Zepbound prescribing information. Updated 2024.
8. FDA. Approval of tirzepatide for OSA. December 2024.
9. CMS. Medicare Part D rules and Medicare Advantage prescription drug benefit. Updated 2025.
10. Eli Lilly. LillyDirect self-pay program. Accessed May 2026.
11. NCQA. Step-therapy protocol exception standards. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting patients with independent licensed clinicians and U.S.-based pharmacies. We do not provide insurance services, file claims, or guarantee coverage decisions. Anthem benefit administration belongs to Anthem and CarelonRx.

Compounded Medication Notice. Compounded tirzepatide is prepared by state-licensed 503A pharmacies under a valid individual prescription. The compounded product is not FDA-approved and is not therapeutically interchangeable with Zepbound. Anthem and CarelonRx do not cover compounded medications.

Results Disclaimer. The PA criteria, step-therapy sequences, and cost figures in this article reflect published Anthem documentation as of writing. Anthem plan benefits change annually and can change mid-year. Your individual plan's specific terms may differ from the typical scenarios described.

Trademark Notice. Zepbound is a registered trademark of Eli Lilly and Company. Anthem, Anthem Blue Cross, Anthem Blue Cross and Blue Shield, CarelonRx, and Elevance Health are registered trademarks of Elevance Health Inc. Wegovy is a registered trademark of Novo Nordisk. FormBlends has no business relationship with Anthem or Elevance Health.